Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Lower LDL C mediated by variants in
2024-09-24
Lower LDL-C mediated by variants in the ACL gene is causally associated with the risk of cardiovascular events. Because, genetic variants that mimic the effect of an ACL inhibitor have the same effect on the risk of cardiovascular events per unit change in LDL-C as variants that mimic the effect of
-
The ambiguity surrounding the role played by the LOXs in
2024-09-24
The ambiguity surrounding the role played by the 15-LOXs in malignant biological processes stems also from the limitations of current animal models, and especially the usage of its 12/15-LOX murine homolog, which can also catalyze the production of 12-HETE. Indeed, the proinflammatory effect of 12-H
-
The transcription factor activator protein AP is
2024-09-24
The transcription factor activator protein-1 (AP-1) is a redox-sensitive transcription factor whose activity is controlled by agents that perturb intracellular thiol concentrations [10,11]. AP-1 is mainly composed of Jun, Fos, and ATF protein dimers [12,13]. AP-1 mediates the regulation of numerous
-
Enasidenib Therefore VEGF and its receptors are expressed in
2024-09-24
Therefore, VEGF and its receptors are expressed in different organs, including the kidneys, the liver and the Enasidenib [55]. In the human placenta, VEGF is mainly synthesized by cytotrophoblast and Hofbauer cells early in the first trimester, whereas Flk-1 and Flt-1 receptors are expressed throug
-
What are the in situ effects of multi site
2024-09-24
What are the in-situ effects of multi-site CaM associations with AT1R? Kai et al. showed that synthetic peptides corresponding to residues 125–137 (rat sequence) in SMD2, 217–227 in the N-terminal side of SMD3, and 304–316 in SMD4JM inhibit to various degrees AngII-induced GTPase activity of isolat
-
br Acknowledgement Work in the McEwan Laboratory is
2024-09-24
Acknowledgement Work in the McEwan Laboratory is funded by the Chief Scientist Office of Scottish Government: Grants ETM-258 and ETM-382. BE is supported by an Erasmus scholarship (D -JENA01). Introduction The equine placenta is a noninvasive transient organ, classified as diffuse and epithel
-
The loss of synaptic proteins such as
2024-09-24
The loss of synaptic proteins such as synaptophysin from the honokiol is indicative of synapse degeneration and provided a good correlate of the degree of dementia in AD [12], [13], [14]. Consequently, the loss of synaptic proteins from cultured primary neurons incubated with Aβ provides a useful i
-
The rescue of the behavioral deficit was associated with a
2024-09-24
The rescue of the behavioral deficit was associated with a significant reduction in the levels of both soluble and insoluble Aβ peptides and their deposition in the Tanshinone I australia of the same animals. In search for the mechanism behind the reduced amyloidosis, we assessed APP metabolism. Co
-
ap4 sale This suggestion was confirmed by immunohistochemica
2024-09-24
This suggestion was confirmed by immunohistochemical studies in which the immunoreactivity of the enzyme was actually higher at the earlier rather than at the advanced stages of the disease. Importantly, a later study showed that the biochemical signature of 12/15LO enzymatic activation (i.e., 12-HE
-
The role of the adaptive immune response in AD is
2024-09-24
The role of the adaptive immune response in AD is not fully understood and previous studies are controversial. In this context, serum levels of T and B lymphocytes were found to be reduced in AD patients, suggesting a decline of the immune response during the course of the disease (Richartz-Salzburg
-
In vivo CA mediate hypoxic
2024-09-23
In vivo CA mediate hypoxic, nutritional, and neurologic stress responses. Stimulation of ADRα2A by these hormones to reduce β-cell metabolism has an obvious role in suppressing insulin secretion (Arun, 2004). Since β-cell metabolism and insulin secretion are linked, mechanisms that inhibit metabolis
-
Pituitary adenylate cyclase activating polypeptide PACAP
2024-09-23
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the secretin/growth hormone-releasing hormone (GHRH)/vasoactive intestinal peptide (VIP) family, with potent anti-inflammatory and potent cytoprotective properties [[6], [7], [8], [9], [10], [11], [12], [13]]. PACAP exists as
-
We observed PACAP immunoreactivity in the molecular layer of
2024-09-23
We observed PACAP2 immunoreactivity in the molecular layer of the cerebellar cortex in zebrafish. This result is consistent with the reporting of PACAP immunoreactivity in the soma and fibers of Purkinje cells and the presence of PACAP mRNA in the Purkinje-cell and granular-cell layers in rats [43].
-
br Materials and methods br Results br Discussions Diabetes
2024-09-23
Materials and methods Results Discussions Diabetes is mainly divided into Type 1 diabetes and Type 2 diabetes [16]. Type 2 diabetes, featured by insulin resistance, results from environmental factors and poor eating habits [2]. Type 2 diabetes accounts for more than 95% of the diabetic pati
-
br Materials and methods br Results
2024-09-23
Materials and methods Results Discussion This study demonstrates that treatment with a selective adenosine kinase inhibitor ABT-702, thereby enhancing extracellular adenosine, can provide partial protection from age-related hearing loss in C57BL/6J mice. Chronic treatment with ABT-702, comm
15895 records 79/1060 page Previous Next First page 上5页 7677787980 下5页 Last page